← back to search

Martin Weltman

Nepean Hospital ·
Area of research
Hepatology · Epidemiology
Research interest
Research interests include Hepatitis C virus research, Liver Disease Diagnosis and Treatment, Hepatitis B Virus Studies, and Liver Diseases and Immunity.
h-index
47
citations
11,611
works
175
NIH funding
primary concept
email

Recent publications

Loss of metabolic adaptation in lean MAFLD is driven by endotoxemia leading to epigenetic reprogramming
Metabolism 2023cited by 34position: middledoi
Systematic review and meta-analysis: Comparing hepatocellular and cholestatic patterns of drug-induced liver injury
iLiver 2023cited by 8position: lastdoi
A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis
Journal of Hepatology 2022cited by 74position: middledoi
A metabolic associated fatty liver disease risk variant in MBOAT7 regulates toll like receptor induced outcomes
Nature Communications 2022cited by 47position: middledoi
Meta‐analysis: hepatitis B reactivation in patients receiving biological therapy
Alimentary Pharmacology & Therapeutics 2022cited by 24position: lastdoi
Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma
Nature Communications 2021cited by 455position: middledoi
Systematic review with meta-analysis: Non-alcoholic fatty liver disease and the association with pregnancy outcomes
Clinical and Molecular Hepatology 2021cited by 53position: lastdoi
IFN-λ3, not IFN-λ4, likely mediates IFNL3–IFNL4 haplotype–dependent hepatic inflammation and fibrosis
Nature Genetics 2017cited by 97position: middledoi
Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy
Clinical Gastroenterology and Hepatology 2017cited by 53position: middledoi
MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C
Nature Communications 2016cited by 128position: middledoi
Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes
Hepatology 2016cited by 124position: middledoi
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease
Nature Communications 2015cited by 174position: middledoi
FibroGENE: A gene-based model for staging liver fibrosis
Journal of Hepatology 2015cited by 77position: middledoi
Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study
Addiction 2015cited by 68position: middledoi
Duodenal eosinophilia and early satiety in functional dyspepsia: Confirmation of a positive association in an <scp>A</scp>ustralian cohort
Journal of Gastroenterology and Hepatology 2013cited by 172position: middledoi
Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: A cross-sectional, observational study
Journal of Crohn s and Colitis 2013cited by 114position: middledoi
Systematic review with meta‐analysis: clinical manifestations and management of autoimmune hepatitis in the elderly
Alimentary Pharmacology & Therapeutics 2013cited by 73position: lastdoi
Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease
Journal of Crohn s and Colitis 2013cited by 53position: middledoi
Heterogeneity of fibrosis patterns in non‐alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways
Liver International 2013cited by 53position: middledoi
Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Infection
Gastroenterology 2013cited by 27position: middledoi
Eradicating hepatitis <scp>C</scp> virus ameliorates insulin resistance without change in adipose depots
Journal of Viral Hepatitis 2013cited by 24position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Guy D. Eslick · The University of Sydney4 papers (2013–2023)Jacob George · The University of Sydney3 papers (2013–2023)Jawaher Alharthi · Taif University2 papers (2022–2023)Mohammed Eslam · The University of Sydney2 papers (2022–2023)Brent A. Neuschwander‐Tetri · Saint Louis University Hospital2 papers (2013–2022)Alissa Walsh · Churchill Hospital2 papers (2013–2013)Duncan McLeod · New South Wales Department of Health2 papers (2022–2023)Ziyan Pan · Shihezi University2 papers (2022–2023)Brian Gloss · Westmead Institute2 papers (2022–2023)Ian C. Lawrance · St John of God Subiaco Hospital2 papers (2013–2013)Hydar El Jamaly · University of Sydney2 papers (2021–2022)Jane M. Andrews · University of the West of England1 papers (2013–2013)Anne Balcomb · New South Wales Department of Health1 papers (2015–2015)Terry Box · University of Utah1 papers (2013–2013)Anita Raposo · UNSW Sydney1 papers (2021–2021)Emily McGovern · UNSW Sydney1 papers (2021–2021)Alexander R. Moschen · Johannes Kepler University of Linz1 papers (2013–2013)Amany Zekry · UNSW Sydney1 papers (2021–2021)Jason Grebely · UNSW Sydney1 papers (2015–2015)Jeong Heo · Pusan National University Hospital1 papers (2022–2022)